OTCMKTS:GMXAY GENMAB A/S/S (GMXAY) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free GMXAY Stock Alerts $28.56 -0.41 (-1.42%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$28.54▼$29.0450-Day Range$26.43▼$31.6852-Week Range$12.10▼$19.00Volume560,041 shsAverage Volume48,553 shsMarket CapitalizationN/AP/E Ratio10.96Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get GENMAB A/S/S alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About GENMAB A/S/S Stock (OTCMKTS:GMXAY)Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.Read More GMXAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMXAY Stock News HeadlinesApril 20, 2024 | msn.comAs lead gen grows on social media, marketers discuss what’s workingApril 17, 2024 | msn.comWhat will RenCen be used for once GM moves headquarters to Hudson's site?April 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 17, 2024 | americanbankingnews.comGENMAB A/S/S (OTCMKTS:GMXAY) Shares Cross Below 50-Day Moving Average of $29.29April 12, 2024 | yahoo.comThe Comics History Behind Genosha, Marvel's Fallen Mutant HavenApril 12, 2024 | msn.comGene variant may protect against Alzheimer'sApril 4, 2024 | msn.comGen X only has $108,600 saved for retirement — but they think they'll need $1.45 million more to live comfortably, a survey foundApril 1, 2024 | msn.com'No one can replace him': Internet abuzz as 'Gen V' Season 2 filming delayed indefinitely following Chance Perdomo's deathApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 1, 2024 | msn.comSeoul’s Glimpse into Automotive History with a Vintage BMW AppearanceMarch 31, 2024 | msn.comAudacious XM a change of direction for BMW’s M divisionMarch 31, 2024 | msn.comGen Z’s Behavior in the Workplace is Both Toxic and Delusional, Report RevealsMarch 30, 2024 | msn.com32 BMW iX EVs were just inducted into this company's fleetMarch 29, 2024 | msn.com"Gen Alpha Needs A Reality Check": 22 Gen Z'ers Were Brutally Honest About The Difference Between Them And Gen AlphaMarch 29, 2024 | msn.comVisalia’s BMX park flattened by the city: what riders want to happen nextMarch 18, 2024 | msn.comRetirement Planning: Nearly Half of Gen X and Younger Generations Fear Savings Not Enough — 4 Reasons It’s Never Too Late To Catch UpMarch 17, 2024 | msn.comGemini: Your finance horoscope - March 17March 16, 2024 | msn.comBMW's annual automotive margin falls below expectationsMarch 15, 2024 | msn.comMG Excelor EV nameplate trademarked, will be brand's 3rd EV after ZS EV & CometMarch 13, 2024 | msn.comAbu Dhabi Launches MGX: A Global Tech VentureFebruary 22, 2024 | bizjournals.comMany managers have a Gen Z problem. Here's how they can solve it.February 22, 2024 | bizjournals.comGen Z is reshaping the workforce. Here's how managers can embrace that change.February 2, 2024 | msn.comFORD EXPLORER ST DRAGS ACURA MDX TYPE S AND GENESIS GV80 WITH SURPRISING RESULTSJanuary 4, 2024 | msn.comGen Zers are balking at the suggestion that a $74,000 salary is considered 'middle class,' with home ownership feeling like a distant dreamAugust 26, 2023 | usatoday.comGet early Labor Day savings of up to $830 on the Samsung Galaxy Tab S9August 25, 2023 | yahoo.comThis Samsung Galaxy phone packs a killer camera — and it's almost 40% off, today onlyMay 9, 2023 | msn.comEarnings Preview For GenmabSee More Headlines Receive GMXAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GMXAY CUSIPN/A CIKN/A Webwww.genmab.com Phone45 70 20 27 28FaxN/AEmployees377Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio10.96 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Jan G. J. van de Winkel (Age 58)Co-Founder, Pres & CEO Mr. David A. Eatwell (Age 58)Exec. VP & CFO Mr. Peter Storm Kristensen (Age 44)Associate Director of Legal & Non-Independent Director Mr. Rick Hibbert (Age 39)Associate Director of Protein Production & Chemistry and Non-Independent Director Dr. Judith V. Klimovsky (Age 61)Exec. VP & Chief Devel. Officer Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors GMXAY Stock Analysis - Frequently Asked Questions How have GMXAY shares performed in 2024? GENMAB A/S/S's stock was trading at $31.84 at the beginning of the year. Since then, GMXAY shares have decreased by 10.3% and is now trading at $28.56. View the best growth stocks for 2024 here. How do I buy shares of GENMAB A/S/S? Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GMXAY) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENMAB A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
